  0086-574-87934126
News
Home / News / Elagolix

Elagolix

Views:39     Author:Site Editor     Publish Time: 2020-08-25      Origin:Site

Elagolix sodium

CAS no. 832720-36-2

M.F :C32H29F5N3NaO5

M.W: 653.571546

CAS no. 832720-36-2


Elagolix

CAS no. 834153-87-6

M.F:C32H30F5N3O5

M.W:631.595

CAS no. 834153-87-6


Elagolix (ABT-620) is an oral gonadotropin-releasing hormone antagonist being studied for the treatment of endometriosis, uterine fibroids and PCOS. For the management of moderate to severe pain associated with endometriosis.

 

Endometriosis is one of the most common gynecological disease in the world. It is estimated that there are more than. 1.76 trillion women are suffering from this.There is one in ten fertile woman in USA having this disease . In China , there are 10% female are attacked by Endometriosis, 40%-60% female with dysmenorrhea are accured by it. Previously, people were using oral contraceptive, progestin, GnRH Antagonist or operation with defects of high side effects or need injection ect. Elagolix is an oral GnRH antagonist with longer half-time, not easy to split by enzyme in body , who can avoid above defects, with bright future.

 

Elagolix has side effects including menopausal-like symptoms such as hot flashes, night sweats, insomnia, amenorrhea, mood changes, anxiety, and decreased bone density among others. Elagolix is a GnRH antagonist, or an antagonist of the gonadotropin-releasing hormone (GnRHR), the biological target of the gonadal production and hence circulating levels of sex hormones such as estradiol, progesterone, and testosterone. Eagolix is a short-acting GnRH antagonist, and can be used to achieve either partial or more substantial suppression of sex hormone levels. Reduced estrogen levels in the endometrium are responsible for the efficacy of elagolix in the treatment of endometriosis.

 

Elagolix is firstly developed by AbbVie Inc and Neurocrine Biosciences. Details as below:

 

First US Approval Date (NDA): 23.Jul,2018 with the trade name of : ORILISSA .

Formulation patent expire on 06 Jul,2024
Trade name : ORILISSA  , Oral tablets , 150 mg once daily or 200 mg twice daily, with or without food
Patent Holder : AbbVie Inc (Canada )  
Until 30.Jun,2019: consumption for 434.4kg ,totally 53.3M dollars( US market 417.3kg, 52.8M)


REQUEST A QUOTE
We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API.

QUICK LINKS

CONTACT US

 Tel: 0086-574-87934126
 Cell: 0086-13600625331
 Fax: 0086-574-87994093
 Whatsapp/Wechat: 0086-13600625331
 Email: info@sandoopharm.com
 Add: 9th Floor, 1#,Smart park, No.98 Chuangyuan Rd, Ningbo, Zhejiang, China

SEARCH PRODUCT

© 2020 Sandoo Pharmaceuticals and Chemicals Co., Ltd. All rights reserved.